Byron L.  Dorgan net worth and biography

Byron Dorgan Biography and Net Worth

Director of Codexis

Byron Dorgan brings experience in policy making, government affairs and financial management having represented North Dakota in the U.S. Senate from 1992 to 2011 and in the House of Representatives from 1981 to 1992. He served as assistant Democratic floor leader, chairman of the Democratic Policy Committee and chairman of the Committee on Indian Affairs and also was the senior senator on the Appropriations, Energy and Commerce committees.

Prior to being elected to Congress, Dorgan served as North Dakota’s state tax commissioner from 1969 until 1980. The author of four books on governmental policy, Dorgan earned a bachelor’s from the University of North Dakota and an MBA from the University of Denver.

What is Byron L. Dorgan's net worth?

The estimated net worth of Byron L. Dorgan is at least $1.02 million as of November 15th, 2023. Mr. Dorgan owns 193,461 shares of Codexis stock worth more than $1,021,474 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Dorgan may own. Learn More about Byron L. Dorgan's net worth.

How do I contact Byron L. Dorgan?

The corporate mailing address for Mr. Dorgan and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Byron L. Dorgan's contact information.

Has Byron L. Dorgan been buying or selling shares of Codexis?

Byron L. Dorgan has not been actively trading shares of Codexis over the course of the past ninety days. Most recently, Byron L. Dorgan sold 20,000 shares of the business's stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $2.11, for a transaction totalling $42,200.00. Following the completion of the sale, the director now directly owns 193,461 shares of the company's stock, valued at $408,202.71. Learn More on Byron L. Dorgan's trading history.

Who are Codexis' active insiders?

Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.

Are insiders buying or selling shares of Codexis?

In the last year, Codexis insiders bought shares 4 times. They purchased a total of 1,166,000 shares worth more than $3,514,910.00. The most recent insider tranaction occured on September, 25th when Major Shareholder Opaleye Management Inc. bought 5,000 shares worth more than $14,300.00. Insiders at Codexis own 2.1% of the company. Learn More about insider trades at Codexis.

Information on this page was last updated on 9/25/2024.

Byron L. Dorgan Insider Trading History at Codexis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2023Sell20,000$2.11$42,200.00193,461View SEC Filing Icon  
10/18/2021Sell20,000$27.94$558,800.00View SEC Filing Icon  
2/21/2020Sell16,702$14.02$234,162.04153,838View SEC Filing Icon  
7/16/2018Sell10,000$15.49$154,900.00190,593View SEC Filing Icon  
See Full Table

Byron L. Dorgan Buying and Selling Activity at Codexis

This chart shows Byron L Dorgan's buying and selling at Codexis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codexis Company Overview

Codexis logo
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $5.28
Low: $5.07
High: $5.48

50 Day Range

MA: $4.22
Low: $2.91
High: $5.81

2 Week Range

Now: $5.28
Low: $2.53
High: $6.08

Volume

3,250,119 shs

Average Volume

569,688 shs

Market Capitalization

$429.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15